Vigabatrin

CAS 68506-86-5 8 current recordsSmall Molecule

Who holds supplier records for Vigabatrin? 8 organisations hold a current record for Vigabatrin: an active US FDA Type II Drug Master File or a CEP. 4 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (8).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Vigabatrin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/vigabatrin

Reading the evidence

  • 8 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    8 of the 8 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Vigabatrin expires 8 Jun 2043. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (8)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Vigabatrin. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • METROCHEM API PRIVATE LTD
    Active DMF 38089 · latest filing Jun 2023
    IndiaCEP
  • MSN Laboratories Private Limited
    Active DMF 27240 · latest filing Jun 2013
    IndiaCEP Company GMP cert on record
  • MSN LIFE SCIENCES PRIVATE LIMITED
    Active DMF 40517 · latest filing Sept 2024
    IndiaCEP Company GMP cert on record
  • SIONC PHARMACEUTICALS PRIVATE LIMITED
    Active DMF 33154 · latest filing Sept 2018
    IndiaCEP Company GMP cert on record
  • APITORIA PHARMA PRIVATE LTD
    Active DMF 33769 · latest filing Apr 2019
    India Company GMP cert on record
  • Divis Laboratories
    Active DMF 31953, 21579 · latest filing Jul 2017
    India Company GMP cert on record
  • Granules India Limited
    Active DMF 35430 · latest filing Dec 2020
    India Company GMP cert on record
  • Hetero Drugs Limited
    Active DMF 33225 · latest filing Sept 2018
    India Company GMP cert on record
Need Vigabatrin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (4)

Certificates of Suitability on the EDQM register for Vigabatrin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
MSN LIFE SCIENCES PRIVATE LIMITED MedakIN
CEP 2024-573 - Rev 00
Vigabatrin
Mar 2026Inspected Oct 2025
Slovakia
SIONC PHARMACEUTICALS PVT. LTD. VisakhapatnamIN
CEP 2019-099 - Rev 01
Vigabatrin
Jul 2025Inspected Mar 2026
Denmark
METROCHEM API PRIVATE LIMITED HyderabadIN
CEP 2023-279 - Rev 00
Vigabatrin
Nov 2024—
MSN LABORATORIES PRIVATE LIMITED Rudraram VillageIN
R1-CEP 2015-344 - Rev 00
Vigabatrin
Nov 2021—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (21 listed products contain Vigabatrin). The latest listed patent expires 8 Jun 2043. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Vigabatrin is an antiepileptic drug used as an adjunctive therapy for patients with refractory complex partial seizures. It irreversibly inhibits the enzyme gamma-aminobutyric acid transaminase (GABA-T), leading to increased levels of GABA in the brain.

Chemical identity

IUPAC name
4-aminohex-5-enoic acid
Canonical SMILES
C=CC(CCC(=O)O)N
InChIKey
PJDFLNIOAUIZSL-UHFFFAOYSA-N
Synonyms
Sabril API, cpp-109, gamma vinyl gaba, gamma-vinyl gaba, mdl 71,754, mdl-71754, rmi-71754, sabril, vigafyde, vigabatrin, (±)-

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Anti-epileptic Agent

Therapeutic areas

EpilepsyNeurology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Vigabatrin?

8 organisations hold an active US FDA Type II Drug Master File or a CEP for Vigabatrin: METROCHEM API PRIVATE LTD (India), MSN Laboratories Private Limited (India), MSN LIFE SCIENCES PRIVATE LIMITED (India), SIONC PHARMACEUTICALS PRIVATE LIMITED (India), APITORIA PHARMA PRIVATE LTD (India), Divis Laboratories (India), Granules India Limited (India) and Hetero Drugs Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Vigabatrin Drug Master Files are active?

METROCHEM API PRIVATE LTD (DMF 38089), MSN Laboratories Private Limited (DMF 27240), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 40517), SIONC PHARMACEUTICALS PRIVATE LIMITED (DMF 33154), APITORIA PHARMA PRIVATE LTD (DMF 33769), Divis Laboratories (DMF 31953, 21579), Granules India Limited (DMF 35430) and Hetero Drugs Limited (DMF 33225). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Vigabatrin have a European Certificate of Suitability?

Yes. 4 organisations hold a valid CEP for Vigabatrin on the EDQM register, including MSN LIFE SCIENCES PRIVATE LIMITED Medak (IN), SIONC PHARMACEUTICALS PVT. LTD. Visakhapatnam (IN), METROCHEM API PRIVATE LIMITED Hyderabad (IN) and MSN LABORATORIES PRIVATE LIMITED Rudraram Village (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Vigabatrin?

Yes. The latest patent listed for an approved US product containing Vigabatrin expires 8 Jun 2043, across 21 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Vigabatrin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Vigabatrin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.